This paper is part of NMJ's 2018 Cognition and Mental Health Special Issue. Download the full issue here.AbstractTraumatic brain injury (TBI) incidence and survivorship is on the rise, leading to an increase in people suffering from post-TBI complications and post-concussion syndrome. Regardless...
A well known rugby league star in Australia, Boyd Cordner (skipper for the Sydney Roosters), announced his retirement today at 29 years of age due to concussion. He hasn't played since last November after being knocked out in the State of Origin series. In this case I think it was one too many concussions over a period of years playing top level football. No doubt he's done the right thing, painful as it is to finish at this age.
It got me thinking about a-msh as a therapeutic treatment to alleviate inflammation post-injury and assist in neuroprotection. I can envisage a time, possibly when off label use and generics have come around, that we will see treatment and recovery based around the use of peptides such as a-msh.
Another well known football player, James Hird, who has had a terrible time over the last few years with a peptide scandal at Essendon Football Club, was known to take Melanotan II. I assume it was based around recovery from training/playing using it as an assist but not related to any head injuries as such. It would be interesting to know how prevalent the use of MT2 or another analogs of a-msh is in the sporting world.
"Endocrine system injury comprises at least 2 known mechanisms: direct mechanical injury and chemical injury from chronic neuroinflammation."
"A similar blunt trauma may occur to the other endocrine areas of the brain, causing a cascade of inflammation that affects neighboring tissue."
"Alpha-Melanocyte–Stimulating Hormone: A more recently understood pituitary hormone, alpha-melanocyte–stimulating hormone (α-MSH), is a neuropeptide with immunomodulatory properties, which may also offer neuroprotection. It acts as a suppressor of proinflammatory cytokine production and induces interleukin (IL)-10 expression, which is one of the most important mediators of the anti-inflammatory effect of α-MSH.26 Alpha-melanocyte-stimulating hormone controls hypothalamic production of melatonin and endorphins. Deficiency creates chronic nonrestful sleep and chronic increased perception of pain. A single administration of α-MSH offers a promising neuroprotective property by modulating inflammation and preventing apoptosis after TBI. However, the potential therapeutic value of α-MSH is limited by its short half-life and melanotropic effects. (Disagree!)